Hazard Risk Reductions Should Not Be Communicated as Relative Risk Reductions for Death in Cancer Clinical Trials: Intentional or Inadvertent?

In the last four decades, median survival has increased in advanced cervical cancer from 7.1 months with single-agent cisplatin to 24 months with doublet chemotherapy plus bevacizumab and pembrolizumab. Coinciding with the emergence of targeted therapy, we observe higher pricing of novel cancer drugs and results presentation aimed to positively impact the audience. The first could result in poor drug affordability and financial toxicity, while the second can give patients a magnified sense of progress. In this review, we briefly comment on study designs that may favor obtaining positive results but, most notably, how results are presented in the latest randomized clinical trials in advanced cervical cancer. We found that survival results are expressed in Hazard Risk (HR) reductions but communicated as a Relative Risk (RR) reduction for death. The HR of the control to the experimental regimen is given by exp[β]. An HR of 0.7 means an HR reduction of 30%. Risk reduction derived from HR may lead to a belief that the intervention can eliminate the chance of the event occurring, but a decreased HR means a reduction in the speed of the event happening, not the chances of it occurring. On the contrary, the “risk reduction” based on RR means that patients have less chance of having the event because RR is a binary measure (alive or dead). Furthermore, Absolute Risks and Number-To-Treat (NNT), in addition to Relative Risk, are omitted. The issue of how the results of cancer

When the studies were positive, and once the products were commercialized, further clinical trials on the drug aimed to optimize the treatments.For example, they studied new combinations, duration, and intensity of the treatments, concurrent vs. sequential schedules, and, of course, head-to-head comparisons to establish their efficacy and toxicity.In other words, medical oncologists interested in optimizing the treatments initiated the studies with minimal influence from the industry providing the research product.
On the other hand, the primary role of Institutional Ethics Committees was to comply with the ethical requirements of any human study in the shortest possible time and with the fewest possible bureaucratic requirements.They understood that promoting and accelerating clinical research was an ethical imperative for both medical researchers and the ethics committees.Many of the oncology clinical trials were initiated by the investigator or groups of investigators, and they could carry them out due to minimal necessary regulation.Of course, at that time, there was no need for Contract Research Organizations (CROs); needless to say, clinical trials were less expensive than they are now.
During that time, the vast majority of the chemotherapy treatment protocols we have today were established, which allowed many tumors to be cured or at least increased survival.Starting in the 1990s, the free market in health began to interfere with each one of the processes involved in the pharmacological therapy of cancer.One of the first consequences was the reduction of public funds for the research and development of cancer therapies, clearing the way for increased private capital to finance the research and development of cancer treatments.This situation was accompanied by a sharp increase in drug prices [9] .This new "form" of clinical research has become a genuine industry where what matters least is that the treatments are affordable for a larger number of people, and it does not even matter that their effectiveness is marginal.The objective of this work is to provide an analysis of the most recent studies on the treatment of advanced cervical cancer on how the industry conveniently presents the results to give a "magnified" vision of the impact of such results for oncologists and patients as well, specifically about hazard ratio (HR), relative risk (RR), and absolute risk (AR) reductions.

Hazard Risk
It is increasingly common for the results of randomized cancer clinical trials to be presented in hazard risk (HR).The most valuable endpoint in many cancer clinical trials is survival, and the measures derived from Kaplan-Meier survival curves are median survival and 1-, 2-, 3-, 5-year survival estimates.However, most survival differences are assessed after adjustment for covariates, commonly using Cox's proportional hazards model [10] .The HR of the control regimen to the experimental regimen is given by exp [β].An HR of 0.7 means an HR reduction of 30%.The survival estimates for patients in the experimental arm increase as the HR decreases; however, the magnitude of these survival estimates depends on the survival estimates of the control arm and is not linear [11][12] .Here are some examples: OS probabilities with HR 0.8 (HRR 20%).When the 1-year OS probability is 80% in control, the 1-year OS probability in the experimental arm would be 84.5%.When the control arm's 1-year OS probability is 20%, the corresponding 1-year OS probability in the experimental arm would be 29%.
OS probabilities with HR 0.2 (HRR 80%).When the control arm's 1-year OS probability is 80%, the 1-year OS probability in the experimental arm is 96%.When the 1-year OS probability is 20% in the control arm, the corresponding 1-year OS probability in the experimental arm would be 72%.A graphical explanation of these concepts is shown in Figure 1.The HR, however, is a dimensionless value; hence its presentation without the absolute benefit over time provides information of limited value.An HR of 0.5 means that, on average, an individual in the group with the higher HR reaches the endpoint (death in survival analysis) first, or an individual with the lower HR reaches the point last.It should be noted that two survival curves with the same HR may lead to different outcomes.As shown in Figure 1, it is readily appreciated that with similar HR (in the example 0.75), the median OS and 3-year, 5-year, and 10-year OS survival rate estimates are different, illustrating that HR is based on relative rankings and not on actual survival times [11][12] .

Relative Risk
Patients and perhaps some medical oncologists may not have a clear and practical understanding of what relative and absolute risk measures mean.Therefore, the pharmaceutical industry takes advantage of this and usually presents the results of cancer clinical trials to obtain a favorable impression from the medical and patient community.Two examples best explaining these concepts are the following: Example 1.
In a study, 100 cancer patients were treated with a control treatment and 100 with an experimental treatment.Two out of 100 patients in the control group died, and in the experimental group, only one died.The relative risk (RR) reduction is 0.50.Two deaths are 100%, and therefore one death is 50%; thus, the relative risk reduction (RRR) is 50% (0.5).
In a study, 98 out of 100 die (98= 100%) in the control arm, while in the experimental arm, 49 out of 98 die (49= 50%); that is, half die, and therefore the RRR is also 50% (0.5).

Absolute Risk
What is the absolute risk reduction (ARR) from these two theoretical studies?In example 1, the ARR is only 1%.That is: 2% of patients died in the control arm while 1% in the experimental arm (2% minus 1% is 1%).This absolute risk reduction is not statistically significant (95%CI-0.237-4.37)as the confidence interval crosses zero.In example 2, the ARR is 49% (98% minus 49% = 49%).Here, the 95%CI is 38.82 -59.18, which is statistically significant.Based on that example, it is easy to understand that the Relative Risk Reduction (RRR) is how much risk is reduced in an experimental group compared to the control group, but the RR does not provide any information about the absolute risk of the event occurring.Accordingly, Absolute Risk is one of the most understandable ways of communicating health risks to the general public.RR and absolute risk use binary data (number of deaths in each group) for their calculation.Figure 2 shows these examples.

Number-to-Treat
The number-needed-to-treat (NNT) provides a clear idea of a treatment's impact on the outcome.In the case of an experimental treatment, how many patients need to be treated to prevent an outcome from occurring in an individual (death, for example)?The NNT is simply the reciprocal of the ARR (100/ARR).Consequently, there is an inverse relationship between the effect (ARR) and the NNT.A treatment with an NNT of 10 is superior to an NNT of 50.Returning to the two hypothetical examples, the NNT of the first example is 100 (100/1=100) with a 95%CI: 22.9 to infinity.Because the upper interval goes to infinity, there is no statistical significance.On the contrary, the NNT in the second example is 2 (100/49 = 2.0) (95%CI: 1.7 to 2.6) because the lower interval is above 1 and the upper is not infinity; the results are statistically significant [13][14] [15] .Relative Risk calculations were performed on https://www.medcalc.org/calc/relative_risk.php, and Absolute Risk and NNT on http://araw.mede.uic.edu/cgibin/nntcalc.pl?2x2=Compute.
The following case illustrates a real-life example of the enormous discordance between RR, AR, and NNT.In Israel, 596,618 people were COVID-19-vaccinated, while 596,618 were in the control arm.A total of 32 patients died in the control arm and 9 in the vaccinated arm.The RRR for "Death due to COVID-19" was 71.88%, while the ARR was 0.004%.
This translates into an NNT of 25,949 (to vaccinate 25,949 individuals to avoid 1 death).For comparison, vaccination with the Smallpox vaccine in India resulted in the following numbers: The vaccinated and control individuals were 2,377 and 3,147, respectively.Deaths in the vaccinated group were 76, and deaths in the control group were 944.The RRR was 89.34% and the ARR was 26.8%.This means that 4 individuals need to get vaccinated to avoid 1 death (NNT 4), [16] .
Hazard Risk Reduction must not be presented as Relative Risk Reduction.
It is imperative to interpret the Hazard Ratio (HR) correctly.Sasheghy [12] stated, "It is common practice when reporting results of cancer clinical trials to express survival benefit based on the HR from a survival analysis as a 'reduction in the risk of death.' Results are commonly presented as follows: drug A reduces the risk of death by 40% based on an observed survival HR of 0.60.This is a typical but incorrect way of communicating survival benefits.HR should not be interpreted as a RR.If we do not distinguish between HR and RR, the 'reduction in risk' (as employed in the publication of clinical trials) implies a durability of the effect in the sense that one is led to believe that for a fraction of the population, the intervention can eliminate the chance of the event occurring.This is not the case.The 'risk reduction' based on HR means a reduction in the speed of the event happening, not the chances of it occurring.On the contrary, the 'risk reduction' based on RR means that patients have a lesser chance of experiencing the event.Because of this, it is easy to understand why scientific journals and the media highlight the results equating the reduction in HR with the reduction in RR.Moreover, the efficacy expressed in ARR often goes unmentioned because ARR is always lower than RR.On the contrary, side effects are always presented with absolute numbers or percentages (AR).
Randomized phase III trials establishing standards of treatment for advanced cervical cancer in the first-line (1L)

Early trials
The information from early trials (Tighpen 1981, Bonomi, 1985, and Omura 1997) [2][3] [17] , established single-agent cisplatin at 50mg/m2 every 3 weeks as the standard of care.No advantage was observed from adding what is now considered older chemotherapy drugs.There are no significant concerns beyond the fact that these studies were not designed or powered for survival parameters but for response rates.Moreover, the studies were not analyzed based on the intention-to-treat (ITT) principle.Nevertheless, the information was considered reasonable to establish single-agent cisplatin at 50 mg/m2 every 3 weeks as the standard of care.

Cisplatin versus cisplatin/paclitaxel (GOG169)
The first indication that a cisplatin-doublet was superior to single-agent cisplatin occurred in 2004 in the GOG169 study.
Among 264 eligible patients, 134 received cisplatin, and 130 received cisplatin-paclitaxel.The ORR was higher with the combination (21% vs. 36%).Though PFS was longer in the combination arm (2.8 vs. 4.8 months, p<0.001), there were no statistically significant differences in median OS (8.8 months vs. 9.7 months).Studies at that time did not report survival with HR.According to the number of deaths reported in each group, the RR was 0.928 (95%CI 0.845-1.019)for an RR of death of 7.15% and a decrease in ARR of death of 6.45%.Both decreases are not statistically significant.Based on improved responses and PFS, the authors encouraged using this combination for further comparative studies [18] .

Cisplatin versus cisplatin-topotecan (GOG179)
The first randomized trial demonstrating increased OS of a cisplatin doublet against a single-agent cisplatin was the GOG179 published by Long et al.Originally, this was a 3-arm study, but the MVAC arm was closed early due to toxicity.
Thus, 294 patients were randomized to cisplatin (145) and cisplatin-topotecan (147).Median PFS was higher in the combination (4.6 and 2.9 months, p=0.014), while the mOS were 6.5 vs. 9.4 months (HR 0.76; p=0.017).Hematological toxicity was higher in the combination [4] .The RR was 0.908 for an RRR of death of 9% and a decrease in ARR of death of 8.08%.Both decreases are not statistically significant.
None of these were statistically significantly different.The arms were comparable concerning toxicity except for leucopenia, neutropenia, infection, and alopecia [5] .The RR and AR are higher in each experimental arm in all three comparisons but not statistically significant.
The first randomized Phase III trial that demonstrated improved survival in the 2L therapy of advanced cervical cancer therapy was recently published [19] .In the trial, patients were assigned to cemiplimab (350 mg every 3 weeks) or the investigator's choice of single-agent chemotherapy.The primary endpoint was OS.Among 608 patients (304 in each group), the median OS was longer in the cemiplimab group than in the chemotherapy group (12.0 months vs. 8.5 months; HR for death, 0.69; p<0.001).Overall, grade 3 or higher adverse events occurred in 45% of the patients who received cemiplimab and in 53.4% of those who received chemotherapy.Table 1 summarizes these findings.

Critical analysis of these randomized trials
The treatment of advanced cervical cancer in the 1L has improved, starting with a median of 7.1 months with cisplatin to 24.4 months with the combination of cisplatin-paclitaxel + bevacizumab + pembrolizumab.It must also be noted that time alone, which may reflect socioeconomic factors, the functioning of health systems, and inclusion criteria in clinical trials, seems to play a role.Though the median OS with cisplatin alone remained unchanged from 1985 to 2004 (7.1-6.5 months), the median OS with cisplatin-doublets (control arms) increased from 9.4 to 13.3 months (3.9 months increase) between 2004 and 2014.The 3.9 months increase observed over these ten years appears the same as the one obtained by adding bevacizumab to the doublet (3.5 months).On the contrary, the addition of pembrolizumab has provided a higher increase (8 months).Regardless of whether someone considers these results excellent, good, average, or bad, the results must be presented in the most objective way possible, avoiding any action to inappropriately influence the medical and patient community so that the treatments are valued in the right dimension of their value.Data presentation of clinical trials in scientific journals and lay press.
The GOG43 compared cisplatin doses, and the GOG110 compared cisplatin against cisplatin combined with mitolactol or ifosfamide.It was not designed to test survival but response rate, nor were they analyzed in the ITT.The results indicated that there was no advantage to increasing the dose of cisplatin beyond 50 mg/m2, nor that mitolactol or ifosfamide could improve survival over cisplatin.The GOG169 and GOG179 were relatively consistent on the magnitude of survival gains in both PFS and OS of either cisplatin-paclitaxel (GOG169) and cisplatin-topotecan (GOG179), although a statistically significant difference in OS was observed only in the GOG179 trial.Likely, the different proportion of patients with previous chemoradiation or radiation alone could account for these results.The GOG204 study comparing four-cisplatin doublets with cisplatin-paclitaxel as the reference arm somehow lent support to the benefit of the cisplatin-doublet [5] .
Interestingly, the GOG179 trial was the first to present survival results in HR; however, the authors did not mention that this combination decreased the risk of death in the NEJM publication.However, the lay press stated, "there was a 24% reduction in the risk of dying in patients taking the combination (https://www.cancernetwork.com/view/topotecancisplatinimproves-cervical-cancer-survival).

GOG240 study
The GOG240 study evaluating bevacizumab was highly publicized.These are some phrases from the title or the body of the publication taken from the lay press: "Avastin met its primary endpoint of improving overall survival with a statistically significant 26% reduction in the risk of death for women who received Avastin plus chemotherapy, compared to women who received chemotherapy alone."https://www.genengnews.com/topics/translational-medicine/avastin-wins-fda-nod-for-

advanced-forms-of-cervical-cancer/ "Avastin plus chemotherapy offered a statistically significant 26% reduction in the risk of death" (https://hospitalpharmacyeurope.com/news/editors-pick/first-new-treatment-authorised-in-a-decade-for-advancedcervical-cancer-patients-in-the-uk/) "Avastin: first molecule in nearly a decade for metastatic cervical cancer. There was a 26% reduction in the risk of death when bevacizumab was combined with chemotherapy." (https://www.ajmc.com/view/avastin-first-moleculein-nearly-a-decade-for-metastatic-cervical-cancer)
The NEJM publication [6] that served as the basis for the above (paragraphs taken from the abstract) states the following: The addition of bevacizumab to chemotherapy was associated with increased overall survival (17.0 months vs. 13.3 months; HR for death, 0.71; 98% CI, 0.54 to 0.95; p=0.004).Bevacizumab, compared with chemotherapy alone, was associated with an increased incidence of hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%).
What would the above look like if HR is not equated to RR and if AR for efficacy and RR for toxicity were mentioned?
It is readily appreciated that data presentations are aimed to positively impact the audience, establishing a 29% lower risk of dying, assuming that the HR is the same as the RR, but it is not.The data indicate that at a median follow-up of 20.8 months, 140 deaths occurred in the chemotherapy control arm (219 patients) and 131 in the chemotherapy plus bevacizumab arm (220 patients).It means that patients who receive the experimental treatment have a 29% less probability on average of reaching death; that is, the speed for the outcome is reduced and therefore results in a statistically significantly higher median survival (17 vs. 13.3 months).However, the RRR of dying is only 6.43%, and the ARR of dying is 3.96%, both cases without statistical significance.The minor ARR translates into an NNT of 22.The survival curves overlap at 30 months of follow-up.On the contrary, if toxicity were expressed in terms of RR and not AR, any patient would hardly accept risks higher than 1000% of suffering serious adverse events if the chances of being alive at 20.8 months are only 3.96% less.
The KEYNOTE-826 study The KEYNOTE-826 [7] study evaluating pembrolizumab was also highly publicized.These are some phrases taken from the media.recurrent, or metastatic cervical cancer" (source).

"Merck's KEYTRUDA® (pembrolizumab) plus chemotherapy, with or without bevacizumab, reduced the risk of death by one-third versus chemotherapy with or without bevacizumab as a first-line treatment for persistent,
"The data showing a 36% reduction in the risk of death are compelling" ( source).
"Adding the checkpoint inhibitor pembrolizumab (Keytruda) to standard chemotherapy -with or without bevacizumab -resulted in about a one-third reduction in the risk of death compared with chemotherapy alone" (source).
The NEJM publication [7] that served as the basis for the above paragraphs (taken from the abstract) discusses the effect of pembrolizumab.
The overall survival at 24 months was 50.4% and 40.4% (HR, 0.67; 95% CI, 0.54 to 0.84; p<0.001).Though not mentioned in the abstract, the body of the manuscript and figures refer to this as "The hazard ratio for death."The most common grade 3 to 5 adverse events were anemia (30.3% in the pembrolizumab group and 26.9% in the placebo group) and neutropenia (12.4% and 9), respectively.
What would the above look like if HR is not equated to RR, and if absolute risks for efficacy and relative risks for toxicity were mentioned?
Efficacy, as stated: The overall survival at 24 months was 50.4% and 40.4% (HR for death, 0.67; p<0.001).The median OS was 24.5 months for pembrolizumab, ranging from 16.3 to 16.5 months for the placebo.
Efficacy, unmentioned: The number of patients that died in each arm was not disclosed, only the total number of deaths, which was 312.This number is shown in Figure 3D and Table S1 of the original publication.Because of that, the RR and AR cannot be calculated; however, estimating the number of deaths in both groups from the 50.4% and 40.4% alive in each arm as the authors refer, the number of dead patients would be 153 and 185 respectively for a total of 338.With these death numbers, the following is calculated (it should be noted that 338 does not correspond to 312).
Toxicity: Expressed as Absolute Risk and Relative Risk.
Among all the randomized trials in advanced cervical cancer in the first-line setting, pembrolizumab has shown the highest increase in the median OS, which is 8 months.Nevertheless, the data presented in scientific journals and press often misinterpret the meaning of HR and equate it with a decreased risk of death when in fact, this indicates that patients who receive pembrolizumab have a 33% less probability on average of reaching death, that is, the speed for the outcome is reduced and therefore results in a higher median survival (24 vs. 16.4 months).While the exact RR cannot be determined because the number of dead patients in each arm was not provided, the RR calculated from the survival curve percentages indicates the patients receiving the drug have a 17% less risk of dying at the reported follow-up.In terms of absolute risk reduction, the number is 10.2%, which indicates that only 10 patients are needed to treat to see a reduction of an event.On the contrary, while it is not incorrect to present toxicity results in absolute percentages, it must be considered that oncologists and patients need to have well-balanced information concerning the benefits and risks of any therapy.Figure 3 provides an overview of these three trials using relative, absolute, and NNT in addition to month increases in median OS. (KEYNOTE-826) months, while the corresponding HR reductions are 24% (0.76), 23% (0.77), and 35% (0.65).In all three cases, the HR reductions are statistically significant.The months gained correspond with the magnitude of risk reduction in terms of HR.Consequently, it is easier to understand that HR reductions are translated to months gained.This is routinely presented, except that HR reductions are treated as RR.
On the other hand, if RR were informed, one could observe that RRR is lower in GOG179 (10%) and GOG240 (5.5%) as compared to KEYNOTE-826 (18%).The statistical significance was only reached in the KEYNOTE-826 trial.This means that patients treated in KEYNOTE-826 in the pembrolizumab arm have an 18% lower relative risk of dying than patients not receiving the study drug.This pattern is the same concerning the AR.Patients receiving pembrolizumab have a 10.2% lower absolute risk for death, which is statistically significant.Accordingly, one needs to treat 13 patients with cisplatintopotecan to avoid one event (death), 22 patients with chemotherapy-bevacizumab to avoid one death, and finally, only 10 patients with chemotherapy-bevacizumab-pembrolizumab in order to prevent death (in this case, the 95%CI is 5.6-42), which is considered statistically significant.The presentation of the results using these measures provides a more informative picture, demonstrating that GOG240 provides less RR and AR reductions and, therefore, the need to treat more patients to observe the effect.On the other hand, the study providing the highest benefit in these four parameters is the KEYNOTE-826 study.
There is growing interest in discussing how the industry influences the design, analysis, writing, and publication of clinical cancer trials.It seems that it has much more weight in designing studies to demonstrate flawlessly and soundly that the study drug is superior, regardless of whether patients are allowed to receive the full options of "standard" therapies or be allowed to crossover or not at progression.If a drug is already approved for the 2L, there is no reason (other than industry interest) not to offer it to patients progressing to the first line.It is argued that if protocols allow for crossover, the study outcome can be negative because of this "contamination."Do these maneuvers of the sponsor have anything to do with doing the best for patients?
In the recent past, it was common to perform studies to optimize treatment for a patient, specifically, combination versus sequential therapies.It has been observed that most of the time, sequential therapies may result in equal survival.The need to add additional arms to prove that the sequential use of novel therapies has similar efficacy in terms of survival should not be underestimated.It is understandable, however, that most, if not all, recent standard-changing trials are sponsored and designed by the pharmaceutical industry, and its interest is to profit as much as possible.Why should sponsors be interested in demonstrating that sequential is the same in terms of survival as combination if sales would decrease with the sequential approach?
At the individual level, the high prices of novel cancer drugs result in poor patient affordability.Even those who can afford these treatments can suffer from financial toxicity, increasing the risk of death [8] .At the societal level, the unsustainability of the current drug development and research model is widely discussed, and potential solutions have been proposed [34][35][36][37] .To overview the magnitude of the problem, let's provide an example of what could represent treating advanced cervical cancer patients with the "standard" platinum-paclitaxel-bevacizumab-pembrolizumab in a middle-high income country.In Mexico, the Federal Budget for Health in 2022 was 9.697 billion USD (at an exchange rate of 1 USD/20 Mexican Pesos (https://www.pef.hacienda.gob.mx/work/models/aVbnZty0/PEF2022/kgp8l9cM/docs/12/r12_ppcer.pdf).In 2019, it was reported that in Mexico, 4,800 women died of cervical cancer (cdn.who.int/media/docs/default-source/countryprofiles/cervical-cancer/cervical-cancer-mex-2021-country-profile-es.pdf?sfvrsn=8a0b4124_38&download=true).If we round up this number to 5,000 and assume that all these women are treated, the cost per patient (retail price) for bevacizumab and pembrolizumab would be 883 billion USD, representing around 9.1% of the total health budget.For any health system, this is nonsensical.

Conclusions
The communication of the results of cancer clinical trials by medical journals and the lay press needs to be balanced.In One can argue against the use of these statistical parameters for their simplicity.However, we must not forget that medicines, if they are marvelous or miraculous, may not require statistical analysis.The need to use more complex and sophisticated statistics parallels their limited effectiveness.It seems all is about demonstrating that the slightest benefit on survival parameters reaches statistical significance to register and commercialize novel drugs.
Figure 4 shows data needed to have a more informative understanding of the value of any therapy tested.These two actions must be taken even if they could confound the clinical trial results.Every effort should be made to embark on clinical trials prioritizing the optimization (in terms of efficacy, toxicity, and cost) of novel drugs, even if this affects the industry's profitability.Sadly, the price of novel cancer treatments is such that no single health system can sustain the current clinical cancer research and commercialization model that uses the "willing-to-pay" approach to establish drug prices.
We all want to achieve real progress in cancer control, but we must be honest about how well we are doing and avoid using statistics conveniently to present the facts more attractively and using superlative adjectives.Exaggerating progress could be offensive to anyone who has lost someone to cancer or is currently fighting cancer.It can be argued that the expectation of cancer treatment advances has shifted from a definitive cure to disease control.Under this statement, relative, absolute, and NNT are undoubtedly useless.However, by accepting this, we impose limits on ourselves for achieving significant strides in cancer.

Figure 1 .
Figure 1.Hazard Risk and survival probabilities

Figure 2 .
Figure 2. Same Relative Risk Reduction, different Absolute Risk Reduction

Figure 3 . 25 Figure 3
Figure 3. Overview of mOS increase in months, Relative Risk Reductions (%), Absolute Risk Reductions (%) and the Number-To-Treat in three key randomized trials At left are the bars for month increases which all were statistically significant, expressed as HR.It must be noted that calculated RR, AR, and NTT are only significant in the Keynote trial.
Qeios, CC-BY 4.0 • Article, November 6, 2023 Qeios ID: F3BC9A • https://doi.org/10.32388/F3BC9A20/25 particular, the correct interpretation and communication of Hazard Risk Reduction meaning are fundamental.It should not be equated with Relative Risk Reductions because it can be misleading to patients and clinicians.Prolonging survival does not mean averting the risk of death.HR means a reduction in the event's speed, not the chances of occurring.Ideally, ARR and NNT should always be used because they are the simplest forms to communicate the treatment effects straightforwardly.After all, patients have the right to know as accurately as possible what to expect from any treatment.

Figure 4 .
Figure 4. Data must be presented in any randomized cancer trial whose aim is survival to calculate Risks and NTT